

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Effectiveness of Blue light photobiomodulation therapy in the treatment of chronic wounds.  
Results of the Blue Light for Ulcer Reduction (B.L.U.R.) Study**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1968330> since 2024-04-05T05:53:05Z

*Published version:*

DOI:10.23736/S2784-8671.21.07067-5

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Effectiveness of Blue light photobiomodulation therapy in the treatment of chronic wounds. Results of the Blue Light for Ulcer Reduction (B.L.U.R.) Study

Marco FRACCALVIERI 1 \*, Giuseppe AMADEO 2, Paolo BORTOLOTTI 3, Marino CILIBERTI 4, Angela GARRUBBA 5, Giovanni MOSTI 6, Salvatore BIANCO 7, Antongiulio MANGIA 1, Maurizio MASSA 3, Valentina HARTWIG 8, Pietro SALVO 8, Elia B. RICCI 9

1San Lazzaro Hospital, Città della Salute e della Scienza, Turin, Italy; 2Unit of Plastic Surgery, “G. Martino” Polyclinic, Messina, Italy; 3Hospital of Lucca, Cittadella della Salute Campo di Marte, Lucca, Italy; 4ASL Napoli 3 Sud, Castellammare di Stabia, Naples, Italy; 5Polo Bari Nord, Hospital of Corato, San Paolo Hospital, ASL/BA, Corato, Bari, Italy; 6Barbantini Clinic, Lucca, Italy; 7AKROS BioScience Srl, Pomezia, Rome, Italy; 8Institute of Clinical Physiology, National Research Council, Pisa, Italy; 9Casa di Cura San Luca, Pecetto Torinese, Turin, Italy

\*Corresponding author: Marco Fraccalvieri, San Lazzaro Hospital, Città della Salute e della Scienza, Via Cherasco 23, 10100 Turin, Italy. E-mail: [marco@fraccalvieri.it](mailto:marco@fraccalvieri.it)

## ABSTRACT

**BACKGROUND:** Lower limb ulcers not responding to standard treatments after 8 weeks are defined as chronic wounds, and they are a significant medical problem. Blue light (410-430 nm) proved to be effective in treating wounds, but there is a lack of data on chronic wounds in clinical practice. The aim of the study was to determine if blue light photobiomodulation with EmoLED (Emoled Srl, Sesto Fiorentino, Florence, Italy) medical device in addition to standard of care is more effective compared to standard of care alone in promoting re-epithelialization of chronic wounds of lower limbs in 10 weeks.

**METHODS:** Ninety patients affected by multiple or large area ulcers were enrolled. To minimize all variabilities, each patient has been used as control of himself. Primary endpoint was the comparison of the re-epithelialization rate expressed as a percentage of the difference between the initial and final area. Secondary endpoints were: treatment safety, pain reduction, wound area reduction trend over time, healing rate.

**RESULTS:** At week 10, the wounds treated with EmoLED in addition to standard care showed a smaller residual wound area compared to the wounds treated with standard of care alone: 42.1% vs. 63.4%

( $P=0.029$ ). The difference is particularly evident in venous leg ulcers, 33.3% vs. 60.1% ( $P=0.007$ ). 17 treated wounds and 12 controls showed complete healing at week 10. Patients showed a significant reduction in pain ( $P=2 \times 10^{-7}$ ).

**CONCLUSIONS:** Blue light treatment in addition to standard of care accelerates consistently the re-epithelialization rate of chronic wounds, especially venous leg ulcers and increases the chances of total wound healing in 10 weeks.

Key words: Wound healing; Wounds and injuries; Ulcer; Low-level light therapy.

Chronic wounds have a substantial impact on the patients' quality of life and are a therapeutic challenge as they often do not respond to standard treatments.<sup>1, 2</sup> The definition of chronic wounds varies in literature, it usually includes a prolonged healing time considered as lack of clinical signs of re-epithelialization for a period that goes from a minimum of four weeks up to three months and the alteration of the sequence of events leading to healing.<sup>3, 4</sup> The objective of the therapies is to manage the healing process reactivating it and sustaining it to achieve non-disturbing cicatrization. Unfortunately, chronic wounds respond poorly even to treatments with advanced dressings. One of the therapies adopted in the field of wound care is photobiomodulation, a specific phototherapy using non-ionizing light sources, including lasers, LEDs and broadband light in the visible and infrared spectrum.<sup>5-7</sup> The wavelengths with the most therapeutic applications are in the red (633 nm), and blue (415 nm) ranges.<sup>8</sup> Blue light (B.L.) induces the transition of the inflammatory phase through the modulation of reacting oxygen species, stimulates granulation, angiogenesis, and enhances the re-epithelialization through the activation of fibroblasts and the release of nitric oxide.<sup>8, 9</sup> The Cytochrome C and the Cytochrome C Oxidase, in the electron transport chain, are made sensitive to blue light by the presence of the Protoporphyrin IX chromophore.<sup>10-15</sup> Once activated by blue light, the cytochrome C and the cytochrome C oxidase contribute to strengthening the cellular respiratory process and they increase ATP production. Blue light supports the lesioned tissue with an increase of energy intake, most needed during the proliferation and remodeling phases. The therapeutic action of blue light can also be explained with the Flavins' absorption, which stimulates the production of ROS (reactive oxygen species) a signal transducers of numerous cellular pathways involved in tissue repair.<sup>16, 17</sup> The modulation of ROS stimulates the transition from the inflammatory phase to the proliferation phase, promoting the macrophages' phenotypic transition from M1 to M2 and enhancing angiogenesis.<sup>18, 19</sup> Several studies demonstrate blue light's efficacy and safety in the treatment of skin lesions, inflammatory acne,<sup>20-23</sup> burns,<sup>9</sup> psoriasis vulgaris<sup>24, 25</sup> and diabetic ulcers.<sup>26</sup> Two literature reviews<sup>27, 28</sup> confirm the efficacy of B.L. in wound treatment. A study on Fluorescent biomodulation<sup>29</sup> shows the general positive impact of light in stimulating wound healing processes in Venous Leg Ulcers and Diabetic Foot Ulcers. Despite the above evidences, there are relatively few experiences methodologically rigorous, conducted in daily clinical practice and focused on chronic wounds, treated in an outpatient setting. EmoLED (Emoled Srl, Sesto Fiorentino, Florence, Italy) is a new medical device emitting blue light (410-430 nm); due to its compact size and ease of use it is suitable for the therapy in outpatient settings on daily clinical practice. EmoLED proved to be effective in the enhancement of re-epithelialization of non-healing ulcers in a case series of 20 chronic ulcers

treated for four weeks recently published.<sup>30</sup> The Blue Light for Ulcer Reduction (BLUR) study was explicitly designed to provide the practitioner with information on the effectiveness and safety of B.L. for the therapy of lower limb chronic wounds in the standard outpatient practice. BLUR study aimed to assess whether the treatment with EmoLED in addition to the Standard of Care (SoC) enhances the re-epithelialization of chronic wounds more than SoC alone.

## **Materials and methods**

BLUR is a multicenter, prospective, controlled study carried in seven specialized outpatient centers located across Italy.

### **Patients**

Patients with chronic wounds of the lower limb of venous, arterial, or mixed origin, and non-healing surgical dehiscence, were enrolled. To minimize variability the investigator chose, on each patient one wound or part of it that was treated with EmoLED in addition to SoC (Treated Arm) and one wound or part of it that were treated with SoC alone (Control Arm) as shown in Figure 1.

The assessment of the wound area was documented by photographs taken at each visit and performed automatically by a dedicated software managed by independent operators unaware of the wound's arm. Each patient has been used as control of him/herself, therefore no masking or randomization was deemed necessary. The protocol defined two cases:

- patients showing one or more wounds >5cm in diameter – the investigator halved the wound according to the larger diameter with a marker. One half of the wound was treated with EmoLED and SoC (treated arm) and the other half with SoC alone (control arm). During the blue light treatment, the control half of the wound was covered with a multi-layered sterile dressing to prevent the exposure to blue light;
- patients with at least two wounds <5cm in diameter – the investigator treated the most severe wound with EmoLED and SoC (Treated Arm) and the other wounds with SoC only (Control Arm). The SoC included ulcer cleansing/debridement, hydrofiber dressing, or hydrofiber with ionic silver in case of signs of infection; in the case of venous and mixed leg ulcers, compression therapy was added when deemed necessary. The wounds or the portions of wounds included in the Treated Arms, in addition to the SoC described above were irradiated with EmoLED for 60 seconds (120 mW/cm<sup>2</sup>; 7,2 J/cm<sup>2</sup>) at each weekly visit this power density being the limit to avoid photothermal effects.

## Study schedule

The investigators collected the patients' data for a period of 10 weeks in 11 weekly visits, from visit V0 (enrolment and first treatment) to visit V10 (end of the study) or Last Observation Carried Forward (L.O.C.F.) if the patients' wound healed before the end of the ten weeks of treatment. From visit V5 on, it was possible not to show up for two non-consecutive visits. At each visit, the investigators evaluated the wound clinical signs: level of exudate, color of the perilesional skin, edges quality, depth, color of the wound bed, presence of granulation tissue. The investigators also took a standardized picture of the wound with an ASUS ZenPad 8.0 (Asus, Taipei, Taiwan) according to a preset procedure. The wound images were analyzed by independent operators at the Institute of Clinical Physiology of the National Research Council (Pisa, Italy) making use of previous experience related to the analysis of ulcers.<sup>31, 32</sup> A custom color-based K-Means<sup>33</sup> algorithm developed in Matlab® (MathWorks, Portola Valley, CA, USA) was applied to segment a wound image in clusters. The software detected a standard reference ruler placed on the wound by the investigator and calculated the conversion factor between the number of pixels and a predefined distance in the ruler (0.5 cm). After selecting the appropriate number of clusters, each cluster area was automatically returned by the software. As for safety, the investigators actively searched for AEs; while the patient reported the wound pain on VAS 0-10 Scale. Independent control of the study was ensured through regular monitoring visits and quality control audits by an qualified independent third party. Table I shows the study schedule.

## Endpoints

The primary endpoint is the comparison of residual wound areas, i.e., the area of treated wounds compared to the residual area of control wounds at the 10th week or at the last observation carried forward (LOCF). The residual wound area is defined as the per cent ratio of the wound area measured at the end of the ten weeks or at the LOCF, compared with the wound the area at the time of enrolment. Residual wound area =  $[(\text{area at the end}/\text{area at enrolment}) \times 100]$ . A smaller residual wound area is then an expression of a more extensive re-epithelialization. The secondary endpoints are: 1) treatment safety in terms of occurrence and importance of adverse events and side effects; 2) pain reduction, measuring at each visit with the VAS Scale method, the patient's pain; 3) trend of reduction of the wound area over time, the wound mean residual area of both arms was measured at each visit; and 4) healing rate, evaluation of the difference in healing time of the two arms.

## Statistical analysis

The statistical planning and data analysis were conducted at the Institute of Information Engineering of the University of Pisa.

## **Sample size**

Based on the scientific literature,<sup>34</sup> a variability of 30% in re-epithelialization at the tenth week has been estimated. The worst-case was represented by a standard deviation (S.D.) of the percentage reduction of the area of venous ulcers of 53%.<sup>35</sup> A population of 83 patients was needed to achieve a beta error of 20% and an alpha error of 5% in assessing the difference between treatments. All the patients with sufficient data to allow the wound image computer analysis were evaluated.

## **Primary endpoint**

The comparison of the residual wound areas, has been analyzed both considering the wounds of each patient as paired data and consolidating the wounds in two separate groups (treated group vs. control group).

## **Secondary endpoints**

The secondary endpoint were the following: 1) E.A.s were listed and described; 2) pain was reported by the patients using a VAS 10 Scale. Patients who completed seven and ten weeks of treatment were analyzed. The data were analyzed using the Friedman test, a non-parametric equivalent of ANOVA, which makes it possible to assess whether there are differences in the value reported in the different measurements made at a group level; 3) trend of the reduction of the wound area over time – the trend was analyzed with the Wilcoxon test which compared the area under the curve (A.U.C.) of the treated and control groups obtained from the values of the residual wound areas at the various follow-up visits; 4) healing rate – the analysis was performed first obtaining Kaplan-Meier curves (K.M.) from the healing time analysis. The K.M. curves express the probability of healing at each follow-up visit. The significance of the difference of the curves was evaluated by applying the non-parametric Wilcoxon test with signs, which considers the coupled nature of the data (paired Prentice-Wilcoxon).

## **Analysis by subgroups**

An analysis of the population divided by etiology was carried out considering three groups: 1) venous leg ulcers; 2) arterial and mixed venous/arterial; and 3) other wounds (surgical dehiscence).

## **Ethical consideration**

The study was conducted following the Helsinki Declaration, the guideline ISO 14155/2011 and the Italian Regulations on clinical trials. The Ethics Committee of the Coordinating Centre granted the study authorization on December 4, 2017, and the Italian Ministry of Health approved the study on

August 8, 2018. All participants provided written informed consent before enrolment. The study is registered on [clinicaltrials.gov](https://clinicaltrials.gov) under the number NCT04018924.

## **Results**

The study was conducted between April 2018 and September 2019.

### **Population characteristics**

A total of 91 patients were screened, and 90 were enrolled in the study (119 wounds), 84 completed the study (6 drop out for unrelated reasons). Sixty-seven patients were evaluable with the software image analysis and their results have been reported. Sixty-eight patients manifested a relevant pain level at enrolment and have been evaluated for the assessment of pain at the seventh week, 45 of them were also evaluable for the assessment of pain at the 10th week of treatment. At the enrolment, the two sexes were equally represented, and the population was predominantly (61.1%) >70 years old. About one-third of patients showed more than one lesion longer than 5cm in one dimension, in the majority of cases (83/90 patients) in the lower limbs. The most frequent etiology was venous leg ulcers (63.02%) and 50 out of 119 wounds had been present for more than 24 months, with an average age of 67.8 months (Table II). The most frequent comorbidities were arterial hypertension (41.1%), type 1 or 2 diabetes mellitus (20.0%) and obesity (8.8%).

### **Primary endpoint**

The primary endpoint was the comparison of the residual wound area in the treated and the control group. The residual area was defined as the per cent ratio of the wound area at the 10th week or at the LOCF and the wound area at the enrolment. The residual wound area (Figure 2) was significantly smaller in the group treated with EmoLED in addition to the SoC than in the group treated with the SoC only (42% vs. 63%). The group treated with EmoLED in addition to the SoC has a more extensive re-epithelialization at LOCF than the group treated with the SoC alone. The pair data analysis (Figure 3) shows a distribution of results of the whole population between -27.9 and +5.2 (P=0.029) where negative numbers mean a positive outcome of the treated lesion versus its control.

## **Secondary endpoints**

### **Treatment safety**

Five SAEs and one AE were recorded during the study. All the SAEs/AEs were related to the patients' comorbidities and were not related to the treatments administered.

### **Pain**

Friedman's test evaluation showed that at the eighth week of treatment the pain (measured with VAS scale) was significantly reduced compared with baseline 3.9 vs. 5.3 respectively ( $P=9 \times 10^{-9}$ ) in the sixty-eight patients showing significant pain levels at enrolment ( $VAS \geq 4$ ). Friedman's test showed that the pain value was significantly lower than baseline 4.6 versus 7.2, respectively ( $P=2 \times 10^{-7}$ ) also in the forty-five patients ending therapy at the 10th week.

### **Trend of the reduction of the wound area over time**

Sixty-four of the 67 patients had enough data to process the A.U.C. Treated and control group progressively reduced the wound area, the difference is close to the statistical significance ( $P=0.076$ ).

### **Healing rate**

Sixty-seven patients were evaluable for the processing of K.M. curves expressing the probability of healing at each follow-up visit. Even if the difference did not reach the statistical significance, the treated group appeared to have a higher probability of healing at the 10th week (0.238 vs. 0.176;  $P=0.16$ ). Furthermore, treated wounds that reached full re-epithelialization are 41,7% more than control (17 treated wounds and 12 control).

### **Sub-group analysis**

In the sub-group analysis, the results of non-venous wounds were hampered by limited sample size and are not reported in this section.

### **Primary endpoint**



The analysis of the subgroups showed that the venous wounds (40 patients) had a marked response to the treatment with EmoLED. More specifically the pair data analysis (Figure 3) of venous ulcers population shows a distribution of results between -51.1 and + 0.2 (P=0.007) providing the evidence of a better outcome in the Treated wounds respect to its Control for almost every patient. The data is also confirmed by the significant prevalence of the treatment versus control in the group analysis showing a lower residual wound area at L.O.C.F. than the group treated with SoC alone, 33.3% versus 60.1% respectively (Figure 4).

## Secondary endpoints

Pain wounds of venous origin (43 patients) had a significant reduction of pain at VAS at the 7th week vs. baseline (3.9 vs. 5.3;  $P=7.6 \times 10^{-5}$ ) and at the 10th week (30 patients; 4.7 vs. 7.2  $P=7.6 \times 10^{-5}$ ).

## Trend of the reduction of the wound area over time

In the wounds of venous origin, the A.U.C. of wounds treated with EmoLED plus SoC was smaller than the A.U.C. of wounds treated with SoC alone. The difference is remarkably close to statistical significance (P=0.06). As for healing rate, no statistical difference was observed for the wound of venous origin (40 patients, P=0.11).

## Discussion

The BLUR study evaluated the performance and safety of a new medical device EmoLED, in addition to SoC in the treatment of chronic wounds in a context of current clinical practice. In our opinion the study has two main reasons of interest: first, it fills a gap in clinical studies specifically targeted to the treatment of chronic wounds in daily clinical practice; second, the assessment of a new medical device (EmoLED) particularly suitable for the use in outpatient settings and everyday clinical practice. The study was carried out with rigorous methodology and an independent quality control. The choice to use each patient as control of her/himself reinforced the homogeneity of the population, although it prevented discrimination in pain data and introduced a positive effect in the control area in the case of single wounds divided in two part and treated partially. Although this effect can influence the data to the disadvantage of the blue light treatment, we believe that the off-target effect cannot compromise the conclusions of the study on the superiority of the treatment compared to the SOC only. The reliability of the data is reinforced by the use of a specific image analysis software for the evaluation of the wound area, which represents a remarkably accurate and unbiased assessment method.

## Limitations of the study

The main limitations of this study are the inclusion of ulcers of different etiology that may respond to therapy in different manners; this difference is partially overcome by the pair data analysis of the results and the small number of wounds of non-venous origin which hampered a comprehensive stratification by etiology. The wounds treated were indeed chronic and challenging to treat, as demonstrated by the median life of the lesion (20.5 months), with a significant share of wounds over 12 months. Treatment with EmoLED in addition to the SoC for 60 seconds once a week induced a substantial reduction in the area of the wound than the SoC alone, as shown in Figure 5.

Study population experienced a marked reduction in pain compared to baseline. This result, although undifferentiated between treatments and controls, strongly suggests an effect of the treatment on pain. The pain reduction was manifest at the week four of treatment, it seems to be correlated to the clinical evidences, reported by investigators, of the resolution of the inflammatory state. The evaluation of results stratified by subgroups showed a particularly marked response of the wounds of venous origin. The EAs observed during the study were unrelated to the treatments and were an expression of the underlying pathologies.

## Conclusions

The BLUR study shows that treatment with EmoLED in addition to the SoC enhances the re-epithelialization of chronic wounds of different etiology with a statistically significant difference compared to therapy with SoC alone, this result seems to be particularly evident in venous leg ulcers. Since the majority of non-healing ulcers are treated on an outpatient basis, in our opinion, it is crucial the availability of a treatment that can accelerate the re-epithelialization of the wound and that it can be carried out on an outpatient basis. We think that this first experience should be followed by studies on other types of wounds, such as inflammatory wounds, and that the action on pain and the whole inflammation phase, should be investigated in the future, as this parameter was particularly evident from what patients reported and the clinical observations indicate.

## References

1. Kirsner RS, Vivas AC. Lower-extremity ulcers: diagnosis and management. *Br J Dermatol* 2015;173:379–90. PubMed <https://doi.org/10.1111/bjd.13953>
2. Järbrink K, Ni G, Sönnnergren H, Schmidtchen A, Pang C, Bajpai R, et al. Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review. *Syst Rev* 2016;5:152. PubMed <https://doi.org/10.1186/s13643-016-0329-y>

3. Nesi-Reis V, Lera-Nonose DS, Oyama J, Silva-Lalucci MP, Demarchi IG, Aristides SM, et al. Contribution of photodynamic therapy in wound healing: A systematic review. *Photodiagn Photodyn Ther* 2018;21:294–305. PubMed <https://doi.org/10.1016/j.pdpdt.2017.12.015>
4. Lazarus GS, Cooper DM, Knighton DR, Percoraro RE, Rodeheaver G, Robson MC. Definitions and guidelines for assessment of wounds and evaluation of healing. *Wound Repair Regen* 1994;2:165–70. PubMed <https://doi.org/10.1046/j.1524-475X.1994.20305.x>
5. Kuffler DP. Photobiomodulation in promoting wound healing: a review. *Regen Med* 2016;11:107–22. PubMed <https://doi.org/10.2217/rme.15.82>
6. Cicchi R, Rossi F, Alfieri D, Bacci S, Tatini F, De Siena G, et al. Observation of an improved healing process in superficial skin wounds after irradiation with a blue-LED haemostatic device. *J Biophotonics* 2016;9:645–55. PubMed <https://doi.org/10.1002/jbio.201500191>
7. Mosca RC, Ong AA, Albasha O, Bass K, Arany P. Photobiomodulation Therapy for Wound Care: A Potent, Noninvasive, Photoceutical Approach. *Adv Skin Wound Care* 2019;32:157–67. PubMed <https://doi.org/10.1097/01.ASW.0000553600.97572.d2>
8. Ablon G. Phototherapy with light emitting diodes: treating a broad range of medical and aesthetic conditions in dermatology. *J Clin Aesthet Dermatol* 2018;11:21–7. PubMed
9. de Alencar Fernandes Neto J, Nonaka CF, de Vasconcelos Catão MH. Effect of blue LED on the healing process of third-degree skin burns: clinical and histological evaluation. *Lasers Med Sci* 2019;34:721–8. PubMed <https://doi.org/10.1007/s10103-018-2647-x>
10. Koch HG, Schneider D. Folding, assembly, and stability of transmembrane cytochromes. *Curr Chem Biol* 2007;1:59–74.
11. Vekshin NL. Light-dependent ATP synthesis in mitochondria. *Biochem Int* 1991;25:603–11. PubMed
12. Mason MG, Nicholls P, Cooper CE. Re-evaluation of the near infrared spectra of mitochondrial cytochrome c oxidase: implications for non invasive in vivo monitoring of tissues. *Biochim Biophys Acta* 2014;1837:1882–91. PubMed <https://doi.org/10.1016/j.bbabi.2014.08.005>
13. Passarella S, Karu T. Absorption of monochromatic and narrow band radiation in the visible and near IR by both mitochondrial and non-mitochondrial photoacceptors results in photobiomodulation. *J Photochem Photobiol B* 2014;140:344–58. PubMed <https://doi.org/10.1016/j.jphotobiol.2014.07.021>

14. Hamblin MR. Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. *Photochem Photobiol* 2018;94:199–212. PubMed <https://doi.org/10.1111/php.12864>
15. Magni G, Banchelli M, Cherchi F, Coppi E, Fracalvieri M, Pugliese AM, et al. Human keloid cultured fibroblasts irradiated with Blue LED light: evidence from an in vitro study; 2019 [Internet]. Available from: [https://www.osapublishing.org/abstract.cfm?uri=ECBO-2019-11079\\_31](https://www.osapublishing.org/abstract.cfm?uri=ECBO-2019-11079_31) [cited 2021, Sep 14].
16. André-Lévigne D, Modarressi A, Pepper MS, Pittet-Cuénod B. Reactive Oxygen Species and NOX Enzymes Are Emerging as Key Players in Cutaneous Wound Repair. *Int J Mol Sci* 2017;18:2149. PubMed <https://doi.org/10.3390/ijms18102149>
17. Dunnill C, Patton T, Brennan J, Barrett J, Dryden M, Cooke J, et al. Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. *Int Wound J* 2017;14:89–96. PubMed <https://doi.org/10.1111/iwj.12557>
18. Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. *Cell Mol Life Sci* 2016;73:3861–85. PubMed <https://doi.org/10.1007/s00018-016-2268-0>
19. Mistry RK, Brewer AC. Redox regulation of gasotransmission in the vascular system: A focus on angiogenesis. *Free Radic Biol Med* 2017;108:500–16. PubMed <https://doi.org/10.1016/j.freeradbiomed.2017.04.025>
20. Gold MH, Andriessen A, Biron J, Andriessen H. Clinical efficacy of self-applied blue light therapy for mild-to-moderate facial acne. *J Clin Aesthet Dermatol* 2009;2:44–50. PubMed
21. Gold MH, Sensing W, Biron JA. Clinical efficacy of home-use blue-light therapy for mild-to-moderate acne. *J Cosmet Laser Ther* 2011;13:308–14. PubMed <https://doi.org/10.3109/14764172.2011.630081>
22. Morton CA, Scholefield RD, Whitehurst C, Birch J. An open study to determine the efficacy of blue light in the treatment of mild to moderate acne. *J Dermatolog Treat* 2005;16:219–23. PubMed <https://doi.org/10.1080/09546630500283664>

23. Tremblay JF, Sire DJ, Lowe NJ, Moy RL. Light-emitting diode 415 nm in the treatment of inflammatory acne: an open-label, multicentric, pilot investigation. *J Cosmet Laser Ther* 2006;8:31–3. PubMed <https://doi.org/10.1080/14764170600607624>
24. Pfaff S, Liebmann J, Born M, Merk HF, von Felbert V. Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris. *Dermatology* 2015;231:24–34. PubMed <https://doi.org/10.1159/000430495>
25. Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. *Dermatology* 2011;223:251–9. PubMed <https://doi.org/10.1159/000333364>
26. Landau Z, Migdal M, Lipovsky A, Lubart R. Visible light-induced healing of diabetic or venous foot ulcers: a placebo-controlled double-blind study. *Photomed Laser Surg* 2011;29:399–404. PubMed <https://doi.org/10.1089/pho.2010.2858>
27. Tchanque-Fossuo CN, Ho D, Dahle SE, Koo E, Li CS, Isseroff RR, et al. A systematic review of low-level light therapy for treatment of diabetic foot ulcer. *Wound Repair Regen* 2016;24:418–26. PubMed <https://doi.org/10.1111/wrr.12399>
28. Jagdeo J, Austin E, Mamalis A, Wong C, Ho D, Siegel DM. Light-emitting diodes in dermatology: A systematic review of randomized controlled trials. *Lasers Surg Med* 2018;50:613–28. PubMed <https://doi.org/10.1002/lsm.22791>
29. Romanelli M, Piaggese A, Scapagnini G, Dini V, Janowska A, Iacopi E, et al.; EUREKA Study Group. Evaluation of fluorescence biomodulation in the real-life management of chronic wounds: the EUREKA trial. *J Wound Care* 2018;27:744–53. PubMed <https://doi.org/10.12968/jowc.2018.27.11.744>
30. Dini V, Romanelli M, Oranges T, Davini G, Janowska A. Blue light emission in the management of hard to heal wounds: a case series. *G Ital Dermatol Venereol* 2020. [Epub ahead of print] PubMed <https://doi.org/10.23736/S0392-0488.20.06691-2>
31. Longobardi P, Hartwig V, Santarella L, Hoxha K, Campos J, Laurino M, et al. Potential markers of healing from near infrared spectroscopy imaging of venous leg ulcer. A randomized controlled clinical trial comparing conventional with hyperbaric oxygen treatment. *Wound Repair Regen* 2020;28:856–66. PubMed <https://doi.org/10.1111/wrr.12853>

32. Dini V, Salvo P, Janowska A, Di Francesco F, Barbini A, Romanelli M. Correlation between wound temperature obtained with an infrared camera and clinical wound bed score in venous leg ulcers. *Wounds* 2015;27:274–8. PubMed

33. Dhanachandra N, Manglem K, Jina Chanu Y. Image Segmentation Using K -means Clustering Algorithm and Subtractive Clustering Algorithm. *Procedia Comput Sci* 2015;54:764–71. <https://doi.org/10.1016/j.procs.2015.06.090>

34. Meaume S, Dissemond J, Addala A, Vanscheidt W, Stücker M, Goerge T, et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: results of a European randomised controlled trial (EARTH RCT). *J Wound Care* 2014;23:105–6, 108–11, 114–6. PubMed <https://doi.org/10.12968/jowc.2014.23.3.105>

35. Hansson C; Cadexomer Iodine Study Group. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. *Int J Dermatol* 1998;37:390–6. PubMed <https://doi.org/10.1046/j.1365-4362.1998.00415.x>

Conflicts of interest.—Salvatore Bianco, Valentina Hartwig and Pietro Salvo received research grants from Emoled Srl; Elia B. Ricci received research grants from KLOX Technologies Inc., personal fees from Deka MELA. S.r.l.

Funding.—This research was funded by a grant from Emoled Srl (Florence, Italy), which provided financial support for the manuscript draft and publication, and from Phidea Live (Milan, Italy), which provided monitoring and quality control audit for the study.

Authors' contributions.—Marco Fraccalvieri, Giuseppe Amadeo, Paolo Bortolotti, Marino Ciliberti and Salvatore Bianco have given substantial contributions to the conception and the design of the manuscript; Valentina Hartwig, Pietro Salvo, Antongiulio Mangia and Maurizio Massa contributed to acquisition, analysis and interpretation of the data; all authors contributed to the manuscript draft, Angela Garrubba, Giovanni Mosti and Bernardino Elia Ricci revised it critically. All authors read and approved the final version of the manuscript.




Figure 1.—A lesion is halved according to the main diameter; one part is treated with SoC alone (C) and one part is treated with EmoLED plus SoC (T).

| TABLE I.— <i>Study schedule.</i>            |    |    |    |    |    |    |    |    |    |    |     |
|---|----|----|----|----|----|----|----|----|----|----|-----|
| Assessment                                  | V0 | V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | V9 | V10 |
| Inclusion/exclusion criteria                |    |    |    |    |    |    |    |    |    |    |     |
| Enrolment                                   |    |    |    |    |    |    |    |    |    |    |     |
| Demography                                  |    |    |    |    |    |    |    |    |    |    |     |
| Patient consent                             |    |    |    |    |    |    |    |    |    |    |     |
| Anamnesis and objective examination         |    |    |    |    |    |    |    |    |    |    |     |
| Wound assessment                            |    |    |    |    |    |    |    |    |    |    |     |
| Treatment                                   |    |    |    |    |    |    |    |    |    |    |     |
| % Reduction of the treated lesion           |    |    |    |    |    |    |    |    |    |    |     |
| Adverse events                              |    |    |    |    |    |    |    |    |    |    |     |
| Difference in healing time of the two areas |    |    |    |    |    |    |    |    |    |    |     |
| Pain reduction                              |    |    |    |    |    |    |    |    |    |    |     |
| Safety                                      |    |    |    |    |    |    |    |    |    |    |     |
| V: visit.                                   |    |    |    |    |    |    |    |    |    |    |     |



| TABLE II.— <i>Characteristics of the wounds: etiology, duration, position and dimensions at the enrollment.</i> |                              |
|---|------------------------------|
| Etiology  | Number of wounds (patients)  |
| Venous  | 75 (56)                      |
| Mixed and arterial  | 25 (18)                      |
| Other   | 19 (16)                      |
| Duration of the wounds  | Number of wounds (patients)  |
| ≤12 months  | 58 (42)                      |
| 13≤ months ≤24  | 11 (8)                       |
| 25≤ months ≤48  | 15 (12)                      |
| 49≤ months <120   | 15 (12)                      |
| ≥120 months   | 20 (16)                      |
| AVERAGE 67.83 (±113.50) months  |                              |
| MEDIAN 20.5 (range 586) months  |                              |
| Position  | Number of lesions (patients) |
| Lower limb. (leg)   | 112 (83)                     |
| Lower limb. (foot)  | 6 (6)                        |
| Abdomen   | 1 (1)                        |
| Initial dimensions  | Number of patients           |
| More than one lesion <5 cm  | 29                           |
| At least one lesion ≥5 cm   | 61                           |




Figure 2.—Residual wound area at the last visit expressed as percentage of the initial area: wounds treated with EmoLED plus SoC and wounds treated with SoC only. Whole wounds population.




Figure 3.—Pair data analysis of the whole population and the three separated sub group considered. Events in favor of the treated group carry the negative sign.




Figure 4.—Residual wound area at the last visit expressed as percentage of the initial area: wounds treated with EmoLED plus SoC and the wounds treated with SoC only. Wounds of venous origin only.




Figure 5.—Improved healing of a wound treated with EmoLED and SoC compared to SoC alone at V0 and V10. Patient age: 72 years; ulcer’s age: 12 months. Pathology: chronic venous insufficiency.